BACKGROUND: The clinical relevance of the amount of human papillomavirus type 18 (HPV18) DNA in cervical tissue (ie, HPV18 DNA load) is unknown. METHODS: Study subjects were 303 women who were HPV18 positive at enrollment into the Atypical Squamous Cells of Undetermined Significance (ASC-US) and Low-Grade Squamous Intraepithelial Lesion (LSIL) Triage Study. HPV18 DNA load, expressed as copies of HPV18 per nanogram of cellular DNA, at enrollment was quantitatively measured. Subjects were followed up semiannually for a period of 2 years for detection of cervical intraepithelial neoplasia 2-3 (CIN2-3). A linear regression model was used to examine associations of CIN2-3 with HPV18 DNA load. All statistical tests were two-sided. RESULTS: CIN2-3 was confirmed in 92 of 303 (30.4%) HPV18-positive women. Among women without CIN2-3, HPV18 DNA load was positively associated with increasing severity of cervical cytology at enrollment (Ptrend < .001). However, among those with CIN2-3, HPV18 DNA load was not associated with severity of cervical cytology at enrollment (Ptrend = .33). The ratios of geometric means of HPV18 DNA load at enrollment among women with CIN2-3, relative to those without, were 6.06 (95% confidence interval [CI] = 0.31 to 117.92) for those with normal cytology at enrollment, 0.50 (95% CI = 0.10 to 2.44) for those with ASC-US, 0.11 (95% CI = 0.03 to 0.46) for those with LSIL, and 0.07 (95% CI = 0.01 to 0.80) for those with high-grade squamous intraepithelial lesion (HSIL). After adjusting for age and coinfection with other high-risk HPVs, a statistically significant association of lower HPV18 DNA load with CIN2-3 was observed among women with LSIL or HSIL at enrollment (P = .02). Within the 2-year period, HPV18 DNA load was unrelated to the timing of CIN2-3 diagnosis. Overall results were similar when the outcome was CIN3. CONCLUSIONS: HPV18 DNA load was higher for women with LSIL or HSIL at enrollment with no evidence of CIN2-3 during the 2-year follow-up period than it was for women with CIN2-3. Thus, testing for high levels of HPV18 DNA does not appear to be clinically useful.
BACKGROUND: The clinical relevance of the amount of human papillomavirus type 18 (HPV18) DNA in cervical tissue (ie, HPV18 DNA load) is unknown. METHODS: Study subjects were 303 women who were HPV18 positive at enrollment into the Atypical Squamous Cells of Undetermined Significance (ASC-US) and Low-Grade Squamous Intraepithelial Lesion (LSIL) Triage Study. HPV18 DNA load, expressed as copies of HPV18 per nanogram of cellular DNA, at enrollment was quantitatively measured. Subjects were followed up semiannually for a period of 2 years for detection of cervical intraepithelial neoplasia 2-3 (CIN2-3). A linear regression model was used to examine associations of CIN2-3 with HPV18 DNA load. All statistical tests were two-sided. RESULTS: CIN2-3 was confirmed in 92 of 303 (30.4%) HPV18-positive women. Among women without CIN2-3, HPV18 DNA load was positively associated with increasing severity of cervical cytology at enrollment (Ptrend < .001). However, among those with CIN2-3, HPV18 DNA load was not associated with severity of cervical cytology at enrollment (Ptrend = .33). The ratios of geometric means of HPV18 DNA load at enrollment among women with CIN2-3, relative to those without, were 6.06 (95% confidence interval [CI] = 0.31 to 117.92) for those with normal cytology at enrollment, 0.50 (95% CI = 0.10 to 2.44) for those with ASC-US, 0.11 (95% CI = 0.03 to 0.46) for those with LSIL, and 0.07 (95% CI = 0.01 to 0.80) for those with high-grade squamous intraepithelial lesion (HSIL). After adjusting for age and coinfection with other high-risk HPVs, a statistically significant association of lower HPV18 DNA load with CIN2-3 was observed among women with LSIL or HSIL at enrollment (P = .02). Within the 2-year period, HPV18 DNA load was unrelated to the timing of CIN2-3 diagnosis. Overall results were similar when the outcome was CIN3. CONCLUSIONS:HPV18 DNA load was higher for women with LSIL or HSIL at enrollment with no evidence of CIN2-3 during the 2-year follow-up period than it was for women with CIN2-3. Thus, testing for high levels of HPV18 DNA does not appear to be clinically useful.
Authors: P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple Journal: J Clin Microbiol Date: 2000-01 Impact factor: 5.948
Authors: A M Josefsson; P K Magnusson; N Ylitalo; P Sørensen; P Qwarforth-Tubbin; P K Andersen; M Melbye; H O Adami; U B Gyllensten Journal: Lancet Date: 2000-06-24 Impact factor: 79.321
Authors: Long Fu Xi; Nancy B Kiviat; Denise A Galloway; Xiao-Hua Zhou; Jesse Ho; Laura A Koutsky Journal: J Infect Dis Date: 2008-08-01 Impact factor: 5.226
Authors: Svetlana Vinokurova; Nicolas Wentzensen; Irene Kraus; Ruediger Klaes; Corina Driesch; Peter Melsheimer; Fjodor Kisseljov; Mattias Dürst; Achim Schneider; Magnus von Knebel Doeberitz Journal: Cancer Res Date: 2008-01-01 Impact factor: 12.701
Authors: M Manavi; G Hudelist; A Fink-Retter; D Gschwantler-Kaulich; K Pischinger; K Czerwenka Journal: Int J Gynecol Cancer Date: 2007-06-22 Impact factor: 3.437
Authors: A N Fiander; K W Hart; S J Hibbitts; G C Rieck; A J Tristram; R W Beukenholdt; N G Powell Journal: J Med Virol Date: 2007-09 Impact factor: 2.327
Authors: Long Fu Xi; Mark Schiffman; James P Hughes; Denise A Galloway; Laura A Koutsky; Nancy B Kiviat Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-05-17 Impact factor: 4.254
Authors: Wendy Theelen; Ernst-Jan M Speel; Michael Herfs; Martin Reijans; Guus Simons; Els V Meulemans; Marcella M Baldewijns; Frans C S Ramaekers; Joan Somja; Philippe Delvenne; Anton H N Hopman Journal: Am J Pathol Date: 2010-09-02 Impact factor: 4.307
Authors: Long Fu Xi; Mark Schiffman; Yang Ke; James P Hughes; Denise A Galloway; Zhonghu He; Ayaka Hulbert; Rachel L Winer; Laura A Koutsky; Nancy B Kiviat Journal: Int J Cancer Date: 2017-01-24 Impact factor: 7.396
Authors: Rachel L Winer; Tiffany G Harris; Long Fu Xi; Kathrin U Jansen; James P Hughes; Qinghua Feng; Carolee Welebob; Jesse Ho; Shu-Kuang Lee; Joseph J Carter; Denise A Galloway; Nancy B Kiviat; Laura A Koutsky Journal: J Med Virol Date: 2009-04 Impact factor: 2.327
Authors: Long Fu Xi; Laura A Koutsky; Philip E Castle; Zoe R Edelstein; Craig Meyers; Jesse Ho; Mark Schiffman Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-12 Impact factor: 4.254
Authors: Long Fu Xi; Zoe R Edelstein; Craig Meyers; Jesse Ho; Stephen L Cherne; Mark Schiffman Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-08-18 Impact factor: 4.254
Authors: Long Fu Xi; James P Hughes; Zoe R Edelstein; Nancy B Kiviat; Laura A Koutsky; Constance Mao; Jesse Ho; Mark Schiffman Journal: J Infect Dis Date: 2009-12-01 Impact factor: 5.226
Authors: Christothea Constandinou-Williams; Stuart I Collins; Sally Roberts; Lawrence S Young; Ciaran B J Woodman; Paul G Murray Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-03 Impact factor: 4.254